Post Marketing Surveillance on Long Term Drug Use of Trazenta Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 08 Nov 2017 Planned primary completion date changed from 1 Jun 2018 to 30 Sep 2018.
- 23 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.